Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials

BACKGROUND: Several clinical trials have shown an increased risk of hypertension with bevacizumab when added to chemotherapy in different types of malignancy; however, the risks of other significant adverse events besides hypertension, specifically in breast cancer, have not been completely elucidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sooyoung, Noh, Yoojin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939922/
https://www.ncbi.nlm.nih.gov/pubmed/29765225
http://dx.doi.org/10.2147/TCRM.S148840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939922/
https://www.ncbi.nlm.nih.gov/pubmed/29765225
http://dx.doi.org/10.2147/TCRM.S148840

Ejemplares similares